The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients

Clinical Nephrology

Volumn 66, Issue 4, 2006, Pages 263-268

  Gursu E M ^a   Özdemir, Alemoz ^a,c   Yalinbas, B ^a   Gursu R U ^a   Canbakan, M ^a   Guven B ^a   Atasoyu, E M ^b   Keskin, A T ^a   Elci A ^a   Baru, Y ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c Halk Cad Arif Hikmetpa a Ap No :76 D :3   (Turkey)

Author keywords

Icodextrin; Insulin resistance; Peritoneal dialysis

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; FERRITIN; FIBRINOGEN; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERTONIC SOLUTION; ICODEXTRIN; INSULIN; IRON; MAGNESIUM; PARATHYROID HORMONE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRON BLOOD LEVEL; MAGNESIUM BLOOD LEVEL; MALE; OBSERVATIONAL METHOD; PARATHYROID HORMONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33749591526     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66263     Document Type: Article

References (32)

1. Acosta AM, Escalona M, Maiz A, Pollak F, Leighton F. Determination of the insulin resistance index by the Homeostasis Model Assessment in a population of Metropolitan Region in Chile. Rev Med Chil. 2002; 130: 1227-1231.
2. Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2001; 17: 80-83.
3. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001; 21: 275-281.
4. Cases A, Vera M, Lopez Gomez JM. Cardiovascular risk in patients with chronic renal failure: Patients in renal replacement therapy. Nefrologia. 2002; 22 (Suppl 1): 68-74.
5. Cheng SC, Chu TS, Huang KY et al. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int. 2001; 21: 282-289.
6. Delarue J, Maingourd C, Couet C, Vidal S, Begros P, Lamisse F. Effect of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int. 1998; 18: 505-511.
7. Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial. 2004; 17: 498-504.
8. Guerrero-Romero F, Rodriquez-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol. 2002; 39: 209-213.
9. Heaton A, Taylor R, Johnston DG, Ward MK, Wilkinson R, Alberti KG. Hepatic and peripheral insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Clin Sci. 1989; 77: 383-388.
10. Hernandez C, Genesca J, Ignasi Esteban J, Garcia L, Simo R. Relationship between iron stores infected by hepatitis C virus: a case-control study. Med Clin (Barc). 2000; 115: 21-22.
11. Howard G, O'Leary DH, Zaccaro D et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 1996; 93: 1809-1817.
12. Ikeda T, Gomi T, Hirawa N, Sakurai J, Yoshikawa N. Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity. Hypertension. 1996; 27: 1180-1186.
13. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000; 15.: 65-70.
14. Lindholm B, Karlander SG. Glucose tolerance in patients undergoing continuous ambulatory peritoneal dialysis. Acta Med Scand. 1986; 220: 477-483.
15. 3 corrects insulin and lipid abnormalities in uraemia. Kidney Int. 1998; 53: 1353-1357.
16. Mak RHK. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol. 1998; 270: 839-844.
17. Mak RHK, Turner C, Thompson T, Haycock GB, Chantler C. The effect of a low protein diet with amino acid/keto acid supplements on glucose metabolism in children with uremia. J Clin Endocrinol Metab. 1986; 63: 985-989.
18. Mak RH. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res. 1996; 40: 304-308.
19. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assesment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-415.
20. Mistry CD, Gokal R. The use of glucose polymer (icodextrin) in peritoneal dialysis: an overview. Perit Dial Int. 1994; 14 (Suppl 3): 158-161.
21. Moberly JB, Mujais S, Gehr T et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int. 2002; (Suppl 81): 23-33.
22. Moorhead JF, Chan MK, Varghese Z. The role of abnormalities of lipid metabolism in the progression of renal disease. In: Brenner BM, Stein JH (eds). The Progressive Nature of Renal Disease 1986. New York: Churchill Livingstone; pp. 133-149.
23. Moro E, Gallina P, Pais M, Cazzolato G, Alessandrini P, Bittolo-Bon G. Hypertriglyceridemia is associated with increased insulin resistance in subjects with normal glucose tolerance: evaluation in a large cohort of subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes. Metabolism. 2003; 52: 616-619.
24. Morrison G. Metabolic effects of continuous ambulatory peritoneal dialysis. Annu Rev Med. 1989; 40: 163-172.
25. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003; 14 (Suppl 4): 315-320.
26. Ravera M, Paoletti E. Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease. Ital Heart J. 2004; (Suppl 5): 436-444.
27. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-1607.
28. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron. 2001; 89: 348-349.
29. Stochmal E, Szurkowska M, Czarnecka D et al. Association of coronary atherosclerosis with insulin resistance in patients with impaired glucose tolerance. Acta Cardiol. 2005; 60: 325-331.
30. Tobey TA, Greenfield MS, Kraemer F et al. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic man. Metabolism. 1981; 30: 165-171.
31. Wu Z, Bao X. Effects of benazepril on insulin resistance and glucose tolerance in uremia. Clin Nephrol. 1998; 5: 108-112.
32. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. 2003; (Suppl 85): S105-S110.